Caris Life Sciences and Ambry Genetics Team Up to Advance Cancer Care
The partnership combines Caris’ somatic and Ambry’s germline testing to provide unique information about the molecular and genetic components of a patient’s cancer.
Read MorePosted by | Jan 31, 2020 | Cancer, Molecular Diagnostics |
The partnership combines Caris’ somatic and Ambry’s germline testing to provide unique information about the molecular and genetic components of a patient’s cancer.
Read MorePosted by | Jan 30, 2020 | Molecular Diagnostics, Tubes |
With a larger draw volume and low hemolysis, cfDNA/cfRNA and cellular gDNA/RNA can be extracted from the same tube, allowing the user to pair results from the same sample.
Read MorePosted by | Jan 30, 2020 | Breast, Cancer, Molecular Diagnostics |
FoundationOne CDx is the only FDA-approved comprehensive genomic profiling test for all solid tumors that incorporates multiple companion diagnostics.
Read MorePosted by Steve Halasey | Jan 27, 2020 | Emerging & Zoonotic Diseases, Infectious Diseases |
Labs gear up to do battle with a potent pathogen.
Read MorePosted by | Jan 14, 2020 | Emerging & Zoonotic Diseases, Infectious Diseases, Molecular Diagnostics, Research |
The test represents a new approach that could be used to detect and kill viruses in the bloodstream.
Read More